Cyclophosphamide |
| Catalog No.GC11145 |
Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastom.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 50-18-0
Sample solution is provided at 25 µL, 10mM.
Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastoma[1].
Cyclophosphamide’s immunomodulatory function was investigated by conditioning macrophages with tumor cell secretome collected from cyclophosphamide treated MM cell lines. CTX-TCS conditioning augmented the migratory capacity of macrophages and increased CD32 and CD64 Fcγ receptor expression on their cell surface. Daratumumab-specific tumor clearance was increased by conditioning macrophages with CTX-TCS in a dose-dependent manner[2]
In vivo，Cyclophosphamide induces early nonapoptotic death of superficial cells, followed by apoptotic death of deeper layers. H&E staining was performed over several days to determine the global urothelial injury and regeneration pattern after cyclophosphamide injection. Compared with uninjured mice, significant sloughing of urothelial cell layers as well as submucosal hemorrhage and inflammation were observed 1 day after cyclophosphamide. cyclophosphamide induces nonapoptotic death of superficial cells starting at 2 hours, followed by apoptotic loss of intermediate and basal cells starting at 4 hours[3]
References:
[1]. Gernaat SAM, von Stedingk H, et al. Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study. Sci Rep. 2021 Feb 1;11(1):2707.
[2]. Naicker SD, Feerick CL, et al. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021 Jan 25;10(1):1859263.
[3]. Narla ST, Bushnell DS, et al. Keratinocyte Growth Factor Reduces Injury and Leads to Early Recovery from Cyclophosphamide Bladder Injury. Am J Pathol. 2020 Jan;190(1):108-124.
| Cell experiment [1]: | |
|
Cell lines |
Multiple Myeloma cell line (MM1.S) |
|
Preparation Method |
MM1.S cells were treated with low dose concentrations of cyclophosphamide over a 48 hour time course, after which in vitro cell death was quantified by flow cytometry. |
|
Reaction Conditions |
2.5, 5, 10, 20µM Cyclophosphamide for 48h. |
|
Applications |
Low-dose cyclophosphamide treatment increased MM cell death in a dose-dependent manner, inducing moderate levels of cell death at 20µM cyclophosphamide after 24 hours and from 10µM cyclophosphamide after 48 hours. |
| Animal experiment [2]: | |
|
Animal models |
C57BL/6 mice |
|
Preparation Method |
C57BL/6 mice were subcutaneously injected with B16F10 cells and daily treated in a low-dose Cyclophosphamide, Paclitaxel and Docetaxel Animals were monitored every 3 days for tumor growth. |
|
Dosage form |
10 mg/kg Cyclophosphamide, intraperitoneal(i.p.) injection |
|
Applications |
Cyclophosphamide chemotherapy significantly delays tumor growth as compared to the control group. At day 19, when all animals in both experimental groups were still alive and comparable, mice treated with metronomic chemotherapy showed a 70% reduction in tumor dimension.Such effect was directly correlated with reduction of CD4+ Tcells and parallel increase of CD8+ Tcells |
|
References: |
|
| Cas No. | 50-18-0 | SDF | |
| Chemical Name | N,N-bis(2-chloroethyl)-2-oxo-1,3,2λ5-oxazaphosphinan-2-amine | ||
| Canonical SMILES | C1CNP(=O)(OC1)N(CCCl)CCCl | ||
| Formula | C7H15Cl2N2O2P | M.Wt | 261.09 |
| Solubility | ≥ 13.05 mg/mL in DMSO, ≥ 11.85 mg/mL in Water with ultrasonic and warming, ≥ 50.8 mg/mL in EtOH. This product is unstable in solution and it is recommended to prepare and use it immediately. | Storage | 4°C, protect from light ,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.8301 mL | 19.1505 mL | 38.301 mL |
| 5 mM | 0.766 mL | 3.8301 mL | 7.6602 mL |
| 10 mM | 0.383 mL | 1.915 mL | 3.8301 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *